SHARE NOW
Cell and Gene Therapy, UBriGene, is expanding into the US market with a state-of-the-art GMP manufacturing facility acquired from Mustang Bio, Inc., a NASDAQ-listed company. The site has successfully manufactured CAR-T products to support clinical trials, as well as performing analytical and process development work supporting the products.
Headquartered in Vancouver, Canada, uBriGene has established global recognition with two GMP manufacturing facilities in China. uBriGene will take over the clinical manufacturing of Mustang Bio’s MB-106, a CAR-T cell therapy treatment for a range of hematological malignancies, including Waldenstrom macroglobulinemia, a rare malignant disorder of the bone marrow and lymphatic tissues.
The newly acquired 27,000-square-foot manufacturing site in Worcester, Boston, Massachusetts, has a suite of clinical facilities for the production of cell and gene therapies and will provide contract analytical services. The move will foresee high-value job and growth opportunities in the greater Boston area, increasing its total global employee number to over 500 employees.
The site has fully integrated technology transfer, quality control testing, manufacturing development, warehousing and cGMP storage capabilities, designed for multiproduct cGMP manufacturing of multiple gene-modified cell types.
“This acquisition is important to uBriGene’s commitment to support the development, clinical, and commercial supply of cell and gene therapies to meet rapidly growing demand,” highlighted Alex Chen, President of uBriGene. “We hope to work together with the University of Massachusetts Medical School to continue to grow the advanced therapy manufacturing ecosystem in the Worcester region.”
How are you enjoying this news article? Let us know your thoughts, here >>
Chen further explained how the partnership between uBriGene and Mustang Bio is beneficial:
“This partnership enables us to expand rapidly to create a North American presence and offer the same high-quality cell and gene therapy development and manufacturing capabilities for the U.S. that we currently provide in Asia, including to support Mustang Bio’s lead clinical-stage CAR-T program.”
Mustang Bio’s CEO also commented on the partnership detailing the potential to advance Mustang Bio’s novel leading cell therapy progression in the US:
“Mustang is excited to be partnering with uBriGene to advance our novel leading cell therapy programs and leverage their global manufacturing and development expertise to progress our advanced cellular therapies through clinical trials in the United States.”
Source: uBriGene Press Release
While we have you…
We are continuously working to better optimize our content for you, our audience. Let us know how we’re doing by ticking the box below, or send us your feedback directly to team@phacilitate.com.
More like this
Eureka Therapeutics Awarded $10.6M CIRM Grant for T-Cell Therapy in Pediatric Liver Cancer
Cell and Gene Therapy Catapult Open New Edinburgh, UK, Facilities
BioCentriq® Unveils LEAP™ Advanced Therapy Platform, Enabling Rapid Patient Access for Early-Stage Biotech Companies
Discover more like this
